Author:
Ye Zhenlong,Li Zhong,Jin Huajun,Qian Qijun
Reference139 articles.
1. Abrams, S. I., Hand, P. H., Tsang, K. Y., & Schlom, J. (1996). Mutant ras epitopes as targets for cancer vaccines. Seminars in Oncology, 23, 118–134.
2. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33, 2780–2788.
3. Arum, C. J., Anderssen, E., Viset, T., Kodama, Y., Lundgren, S., Chen, D., & Zhao, C. M. (2010). Cancer immunoediting from immunosurveillance to tumor escape in microvillus-formed niche: A study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer. Neoplasia, 12, 434–442.
4. Aurisicchio, L., Roscilli, G., Marra, E., Luberto, L., Mancini, R., La Monica, N., & Ciliberto, G. (2015). Superior immunologic and therapeutic efficacy of a xenogeneic genetic cancer vaccine targeting carcinoembryonic human antigen. Human Gene Therapy, 26, 386–398.
5. Banchereau, J., & Palucka, A. K. (2005). Dendritic cells as therapeutic vaccines against cancer. Nature Reviews Immunology, 5, 296–306.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献